
PRME Stock Forecast & Price Target
PRME Analyst Ratings
Bulls say
Prime Medicine is a promising biotechnology company with a potential best-in-class AATD program that targets a significant unmet need. Its versatile prime editing platform, validated by early clinical data and a partnership with BMS, adds value to its other pipeline programs, including its potentially best-in-class AATD program. With major upcoming catalysts and a strong management team, Prime Medicine is poised for success.
Bears say
Prime Medicine is a relatively new company with a promising but unproven gene-editing technology for the treatment of genetic diseases, such as Wilson Disease and AATD. However, with limited financial resources and no approved therapies, the company faces significant financial and commercialization risks. Furthermore, competition from other genetic medicines and potential high pricing of its therapies may limit the company's market potential, leading to a negative outlook for its stock.
This aggregate rating is based on analysts' research of Prime Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.
PRME Analyst Forecast & Price Prediction
Start investing in PRME
Order type
Buy in
Order amount
Est. shares
0 shares